Top Page
The United Laboratories International Holdings
(3933)
The United Laboratories International Holdings (3933) vs. iShares MSCI Hong Kong ETF (EWH)
The United Laboratories International Holdings Business Overview & Revenue Model
The United Laboratories International Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.10B | 13.76B | 13.74B | 11.33B | 9.70B | 8.77B |
| Gross Profit | 6.66B | 6.08B | 6.33B | 4.97B | 4.21B | 3.81B |
| EBITDA | 3.88B | 3.35B | 3.98B | 2.54B | 1.98B | 1.83B |
| Net Income | 3.06B | 2.66B | 2.70B | 1.58B | 988.10M | 702.99M |
Balance Sheet | ||||||
| Total Assets | 29.43B | 25.83B | 21.02B | 18.98B | 16.33B | 14.96B |
| Cash, Cash Equivalents and Short-Term Investments | 9.01B | 6.33B | 4.26B | 4.74B | 3.33B | 3.00B |
| Total Debt | 5.13B | 3.16B | 1.50B | 2.46B | 1.84B | 2.21B |
| Total Liabilities | 13.82B | 11.40B | 8.27B | 8.37B | 6.99B | 6.35B |
| Stockholders Equity | 15.57B | 14.39B | 12.73B | 10.61B | 9.34B | 8.61B |
Cash Flow | ||||||
| Free Cash Flow | 417.70M | 1.33B | 977.50M | 1.25B | 1.06B | 1.04B |
| Operating Cash Flow | 1.35B | 3.20B | 2.44B | 2.03B | 1.54B | 1.57B |
| Investing Cash Flow | -1.20B | -1.73B | -1.56B | -594.92M | -587.22M | 166.76M |
| Financing Cash Flow | -373.46M | 596.91M | -1.36B | -24.17M | -620.93M | -1.91B |
The United Laboratories International Holdings Technical Analysis
The United Laboratories International Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $33.45B | 12.13 | 14.91% | 3.76% | -0.45% | 9.00% | |
73 Outperform | HK$31.09B | 14.75 | 12.65% | 2.97% | 10.56% | -13.58% | |
68 Neutral | HK$31.10B | 10.23 | 5.90% | 2.76% | ― | ― | |
65 Neutral | $24.88B | 6.94 | 21.02% | 4.93% | 0.39% | 4.94% | |
65 Neutral | $33.79B | 18.88 | 10.01% | 2.12% | 11.78% | 19.06% | |
54 Neutral | £21.19B | 5.83 | 48.58% | ― | -1.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
The United Laboratories International Holdings Corporate Events
The United Laboratories International Holdings Limited announced the payment of an interim dividend of RMB16 cents per share for the first half of 2025, which will be converted and paid in Hong Kong dollars at a rate of HK$0.175070 per share. This payment is scheduled for 15 October 2025, benefiting shareholders listed as of 30 September 2025, reflecting the company’s commitment to returning value to its shareholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited announced an interim dividend of RMB 0.16 per share for the six months ending June 30, 2025, with the payment to be made in Hong Kong dollars at an exchange rate of RMB 1 to HKD 1.09419. This announcement reflects the company’s ongoing commitment to providing shareholder value and may impact investor sentiment positively as it highlights financial stability and profitability.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited announced the approval of a clinical trial for its new drug, UBT37034, targeting overweight and obesity. This approval, granted by both the China National Medical Products Administration and the U.S. FDA, marks a significant step in the company’s efforts to enhance its competitiveness in the biopharmaceutical industry, potentially benefiting its shareholders.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited is a Cayman Islands-incorporated company operating in the pharmaceutical sector, focusing on the production and sale of intermediate products, bulk medicine, and finished products, including insulin and antibiotics.
The United Laboratories International Holdings Limited has established a Sustainability Committee to enhance its ESG management and performance. This initiative aims to integrate ESG considerations into business decision-making processes, ensuring compliance with applicable laws and regulations. The Committee will focus on environmental, social, and governance matters, and is supported by a Sustainability Working Group responsible for implementing the Group’s ESG initiatives. This move is expected to improve stakeholder recognition of the company’s sustainability efforts and position it as a responsible enterprise in the industry.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited announced its interim financial results for the six months ending June 30, 2025, reporting a 4.8% increase in revenue to RMB 7.52 billion compared to the same period in 2024. The company also saw significant growth in profitability, with EBITDA rising by 23.3% and profit attributable to owners increasing by 27%, reflecting strong operational performance and effective cost management.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited has announced an interim cash dividend of RMB 0.16 per share for the six months ending June 30, 2024. This announcement reflects the company’s financial performance and commitment to returning value to shareholders, with key dates for the dividend process outlined, including an ex-dividend date of September 25, 2025, and a record date of September 30, 2025.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited has announced the composition of its board of directors and the roles within its various committees. This announcement highlights the company’s governance structure, which includes a mix of executive and independent non-executive directors, and outlines the leadership of its five key committees, indicating a structured approach to corporate governance.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited has issued a positive profit alert, indicating an expected net profit of approximately RMB1.85 billion for the first half of 2025, up from RMB1.49 billion in the same period in 2024. This increase is largely attributed to a significant license fee income from Novo Nordisk A/S, despite declines in segment profits for intermediate products and bulk medicine.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited has announced that its board of directors will meet on August 28, 2025, to review and approve the company’s interim results for the first half of the year and to consider the declaration of an interim dividend. This meeting is significant as it will provide insights into the company’s financial performance and potential shareholder returns, impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
The United Laboratories International Holdings Limited has successfully completed the placing of 156,000,000 new shares, raising net proceeds of HK$2,168.2 million. The funds will be used primarily for capital expenditure on manufacturing facilities, including the Inner Mongolia and Zhuhai plants, as well as for expanding international business and general corporate purposes.
The most recent analyst rating on (HK:3933) stock is a Hold with a HK$15.29 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.